Talk:Amgen

Removal of certain "key people" from infobox
Courtland 04:34, 8 November 2005 (UTC)
 * Chad Carlile: this person is not listed on the Amgen.com website.
 * The inclusion of this person is presumably based on information found in the Fall 2004 APSA Newsletter (see http://www.psychology.sdsu.edu/APSA_News_F-04.pdf) in which his role is described as follows: "Within Amgen, Chad works as a Senior Curriculum Designer at the organization’s headquarters in Thousand Oaks, CA. His group is part of a larger training function in the organization that trains new and existing employees on task- and product-specific qualities."
 * Removing this piece of information is a matter of addressing notability of content
 * Mark Hutt, Pritesh Patel: these people are not listed on the Amgen.com website.
 * I have not been able to find information that links a "Mark Hutt" or "Pritesh Patel" or "Hutt" or "P. Patel" to Amgen through basic searches with Google
 * Removing this piece of information is a matter of addressing verifiability of content

Article search redirects to AMGEN
I am wondering if someone might know the reasoning why a search for "Immunex" redirects to this Amgen article? I ask this because Immunex (a Biotech R&D company) was founded in the 1980's and had quite a notable history of accomplishments before it was acquired by Amgen in 2001. If no one has any objections, I would like to set up an Immunex article, which can, of course, redirect the reader to the Amgen article, should they want to read more about the company by whom Immunex was acquired. Does anyone know how I can find out if there was formerly a Wiki article on Immunex? Thank you kindly. Tell someone (talk) 02:00, 4 April 2009 (UTC)

Remove?
This looks more like advertisement than en encyclopaedial article. — Preceding unsigned comment added by Siriussounds (talk • contribs) 11:35, 9 February 2011 (UTC)


 * The way to deal with that is to add more WP:NPOV material critical of the company, maybe in a "Criticism" section. Here's a couple http://www.nytimes.com/2011/10/25/health/25amgen.html http://www.nytimes.com/2013/01/20/us/medicare-pricing-delay-is-political-win-for-amgen-drug-maker.html?hp&_r=0&gwh=9634789278CF43115AE6C27876406B86&pagewanted=all --Nbauman (talk) 02:47, 20 January 2013 (UTC)
 * The article has gone too far the other way now, the criticism section is the largest section of the article. And realistically the Sensipar trial can hardly be considered criticism - clinical trials have deaths. The wording alone is ambiguous; Sensipar is still available for use, it was dosages in children with ESRD that were being tested. Mc8755 (talk) 23:01, 1 May 2013 (UTC)

Agreed article is now mainly a timeline that has no NPOV at all. Article needs a rewrite for content and POV — Preceding unsigned comment added by 86.44.4.67 (talk) 18:28, 7 October 2013 (UTC)

Blacklisted Links Found on the Main Page
Cyberbot II has detected that page contains external links that have either been globally or locally blacklisted. Links tend to be blacklisted because they have a history of being spammed, or are highly innappropriate for Wikipedia. This, however, doesn't necessarily mean it's spam, or not a good link. If the link is a good link, you may wish to request whitelisting by going to the request page for whitelisting. If you feel the link being caught by the blacklist is a false positive, or no longer needed on the blacklist, you may request the regex be removed or altered at the blacklist request page. If the link is blacklisted globally and you feel the above applies you may request to whitelist it using the before mentioned request page, or request it's removal, or alteration, at the request page on meta. When requesting whitelisting, be sure to supply the link to be whitelisted and wrap the link in nowiki tags. The whitelisting process can take its time so once a request has been filled out, you may set the invisible parameter on the tag to true. Please be aware that the bot will replace removed tags, and will remove misplaced tags regularly.

Below is a list of links that were found on the main page:


 * http://www.pharmaceutical-business-review.com/companies/amgen_inc
 * Triggered by  on the local blacklist

If you would like me to provide more information on the talk page, contact User:Cyberpower678 and ask him to program me with more info.

From your friendly hard working bot.— cyberbot II NotifyOnline 17:05, 8 December 2013 (UTC)

Amgen Center for Science Learning
California Science Center article shows "Amgen Center for Science Learning", another wiki editor thought it was irrelevant on Amgen article and deleted it. Please discuss in Talk if compelled to further discuss this simple addition. Just trying to expand the better an article since another article already mentions it. Neoking (talk) 23:39, 3 February 2016 (UTC)
 * Thanks for opening a discussion on Talk. The most important issue I had, is that source does not describe it as a separate building. Separately, it is also trivial with regard to everything Amgen does.  Why is it important from your perspective?   If there were an independent source about it (coverage in a newspaper or something) you would have a stronger case to make; it is difficult with a source like this to justify it.Jytdog (talk) 23:44, 3 February 2016 (UTC)
 * Please do work this through, thanks. No reason to get upset, just talk it through!  Jytdog (talk) 01:21, 4 February 2016 (UTC)
 * Here is what the source you are citing says: "The Wallis Annenberg Building houses eight classrooms, administrative offices, a multi-purpose room and the school library. In addition, the Wallis Annenberg building includes over 80,000 square feet for the Science Center’s education division, the Amgen Center for Science Learning." This makes it really clear that the Amgen Center for Science Learning is inside the Wallis Annenberg Building"  Now maybe that doesn't match reality (I don't know, i have never been there) but that is what the source you have provided says. Jytdog (talk) 01:23, 4 February 2016 (UTC)
 * by the way, here is the content you wanted to add: ""Amgen Center for Science Learning", an Amgen Sponsored Building in California Science Center. "


 * Do you see that you describe it as an "Amgen Sponsored Building "? (I am unsure what is up with the Germanic spelling, and I don't know why you put this in the external links section, and as I said above this would really need some kind of independent sourcing to show it is important enough to give any weight to....) but the key issue is that it is just wrong, based on the source. Jytdog (talk) 01:55, 4 February 2016 (UTC)


 * Its funny how someone who thinks they are a Wikipedia Editor and don't know how to use Google Maps or MapQuest or the like to verify Wallis Annenberg Building (USC) is 2 blocks North of California Science Center/Exposition Park and not what I cited. But, its ok you can sit and guard dog your page and keep being a WikiTroll, ignorance is an excuse for reverting other peoples work.  So you win by default, also its only a small contribution I tried to make.  There are plenty of sources showing Amgen contributions.  https://students.ucsd.edu/sponsor/amgen/#Other-Amgen-centers and there are plenty of online articles about Amgen generous donation to California Science Center and Dr. Theodore T. Alexander, Jr. Science Center School its easy to make others work but not do the work yourself.  You can keep guard dogging your page all you want.  Wikepedia is no longer a viable scholarly source due to people like you Jytdog. Its a shame how you feel so strongly about this article, have fun sitting on it.  Neoking (talk) 16:50, 4 February 2016 (UTC)
 * everything in WIkipedia is based on sources. I have reacted to the sources you brought and even quoted it above. You are not dealing with what it says, and I don't know what to do about that. I understand you are not happy with what it says but that is weird because you are the one who brought it.  I just don't know what to do with that. Jytdog (talk) 17:53, 4 February 2016 (UTC)


 * Neoking, the relevant policy for both of the items you were trying to add is WP:SEEALSO. The See Also section is reserved for subjects that have complete Wikipedia articles written about them. Since neither the Amgen Center for Science Learning nor the Dr. Theodore T. Alexander, Jr. Science Center School have Wikipedia articles, they do not belong in the See Also section. You could try and create articles on them if you wished, although I'm not sure either of them independently meet Wikipedia's notability requirements for articles. Softlavender (talk) 09:28, 6 February 2016 (UTC)

COI edit request re: Russian controversy
Hi! I'm a conflict of interest editor for Amgen, a client of my employer, Porter Novelli. I have a quick edit request for this article: removing the “Controversy” paragraph about Amgen’s presence in Russia. Here’s my thinking: Thanks for your time and assistance! Mary Gaulke (talk) 16:29, 17 May 2022 (UTC)
 * The Yale report is a primary source, so ideally it should be supported by secondary media coverage of the same information (e.g. as in Emirates (airline)). I couldn’t find any independent media sources covering any kind of backlash or criticism against Amgen for its inclusion in the report.
 * I looked up many of the other organizations listed in the report, and from what I can tell, the only other organizations on the list with mentions in their articles had them added by either the same IP user who added the section to this article or, who added almost identical wording to several more articles. All of these edits date back to April 28/29, and I didn’t see any substantive discussion in talk in the few weeks since about use of the Yale source. There is some inconclusive discussion of the source at Talk:Corporate responses to the 2022 Russian invasion of Ukraine, where contends, "Yale team obviously did a lot of similar work and their list is over 450 records (some non-companies), BUT no links to company profile, expanded details, or citations make their list ambiguous at best."
 * If the reference is retained, I request that the phrase "Amgen refused to join the international community" be revised or deleted as interpretation of the source, since the source simply states that Amgen is still operating in Russia.
 * Additionally, if the reference is retained, two pieces of context I believe are relevant to include:
 * Amgen has donated $500,000 in disaster relief grants to International Medical Corps and Project Hope and provided matching funds for employee donations to select charities supporting humanitarian efforts in Ukraine.
 * Many pharmaceutical companies have opted to continue operations in Russia or to suspend only some operations in order to provide healthcare products and medicine to Russian people.


 * Red information icon with gradient background.svg Not done for now: The paragraph is appropriate given the circumstances, so this is denied. However, it could use some improvement. Quetstar (talk) 00:43, 19 May 2022 (UTC)
 * Thanks for the response! Would you please clarify how the paragraph is appropriate, given the concerns I raised about interpretation of a primary source? I want to understand what I'm missing here. Also, is there anything I can do to facilitate the improvement? Mary Gaulke (talk) 16:56, 19 May 2022 (UTC)
 * The paragraph is appropriate in the sense that it describes Amgen's stance on Russia amidst its illegal invasion of Ukraine. Removing it would basically constitiute whitewashing. As for the improvements, the text should be reformatted to make it more compliant to standards. Quetstar (talk) 11:04, 20 May 2022 (UTC)
 * Understood. How about something like this?
 * During the 2022 Russian invasion of Ukraine, Amgen was one of several pharmaceutical companies that opted to continue operations in Russia. Research from Yale University updated on April 28, 2022, listed Amgen among the companies defying demands for exit or reduction of activities. In March 2022, Amgen donated $500,000 in disaster relief grants to International Medical Corps and Project Hope and provided matching funds for employee donations to select charities supporting humanitarian efforts in Ukraine.
 * Thanks! Mary Gaulke (talk) 20:05, 23 May 2022 (UTC)
 * One more thought – would this be better incorporated into the "History" section rather than having its own section, per WP:CSECTION? Mary Gaulke (talk) 19:11, 24 May 2022 (UTC)
 * Would love your feedback if you have a moment. Or, I can open up a new request. Thanks! Mary Gaulke (talk) 16:00, 2 June 2022 (UTC)
 * Sorry for the delay, I'm quite busy right now, so I am deferring this to other editors. As for the paragraph you proposed, it looks good IMO, but i think that a second opinion from a more experienced editor will do the trick. You're welcome to make a new request at any time. Quetstar (talk) 21:52, 2 June 2022 (UTC)
 * No problem – I'll open up a new request. Thanks for the reply! Mary Gaulke (talk) 21:39, 4 June 2022 (UTC)

COI Edit Request April 2023
Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.

Lead

 * Update the second mention of "Thousand Oaks, California" to just "Thousand Oaks" – not necessary to repeat the state two sentences in a row.


 * Update


 * Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County.
 * to
 * Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 (8.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff and, as of 2016, has a presence in approximately 100 countries. The company develops products in six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.


 * Delete


 * Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
 * Given that the source is more than 20 years old, I think it's fair to say this isn't the best representation of the organization's current goals.


 * Update


 * In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases.
 * to
 * In 2019, the company's largest selling products were Enbrel (etanercept), a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy.


 * Update


 * Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
 * to include recent products, as follows:
 * Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).


 * Move


 * Amgen sponsored the Tour of California from 2011 to 2017.
 * from the lead into the History section.

History

 * Move the following sentence from the intro into the history section as the first sentence:


 * Amgen was established in Thousand Oaks, California, in 1980.

Thank you for your time and assistance. JZindler (talk) 20:20, 17 April 2023 (UTC)


 * Yellow check.svg Partly done: "Other marketed products" were not included because they are not supported by a reliable source. Throast  {  { ping }} me! (talk &#124; contribs) 16:07, 26 June 2023 (UTC)


 * Thank you for your help! Appreciate it. 65.30.128.134 (talk) 20:09, 26 June 2023 (UTC)

COI Edit Request June 2023
Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.

Timeline

 * Add to beginning of "1980" bullet:
 * Founded in Thousand Oaks, California, as Applied Molecular Genetics, Amgen was backed by a small group of venture capitalists. Its focus in early days was on recombinant DNA technology and recombinant human insulin.


 * Add to end of "1980" bullet:
 * In October, Amgen named George Rathmann its first president and chief executive officer.


 * Add:
 * 1983. On June 17, Amgen went public, selling two million common shares and raising nearly $40 million.  That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin had a breakthrough in finding and cloning the erythropoietin gene, a protein created in the kidney that stimulates red blood cell production. Lin's team created what would become Epogen (epoetin alfa).
 * 1984. In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.
 * 1985. Amgen researcher Larry Souza and his team cloned granulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).
 * 1988. In October, Gordon Binder was named CEO, succeeding George Rathmann.


 * Update
 * 1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure. Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.
 * to
 * 1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).
 * The synopsis currently in the article doesn't reflect the product label.


 * Add:
 * 1993. In March, Amgen opened a new manufacturing facility in Puerto Rico, which later became the company's flagship manufacturing site.
 * 1994. Amgen became the fifth company to receive the U.S. Department of Commerce's National Medal of Technology and Innovation, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients. Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).


 * Add:
 * 2000. In May, Kevin Sharer became Amgen's third CEO, following Gordon Binder's retirement.
 * 2001. Aranesp received FDA approval in September.
 * 2002. At the beginning of the year, the FDA approved Neulasta. In July, Amgen acquired Immunex, the developer of Enbrel (etanercept).
 * 2004. Sensipar (cinacalcet) was approved by the FDA. Also, Amgen acquired Tularik, another biotechnology company, expanding the company's research and development pipeline.
 * 2006. In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal cancer. Vectibix was approved by the FDA in September 2006.
 * 2008. In August, Nplate (romiplostim) was approved by the FDA.


 * Add:
 * 2011. Amgen acquired a manufacturing facility near Dublin, Ireland, in March. In May, Amgen acquired BioVex, developer of Imlygic (talimogene laherparepvec). In December, Amgen and Watson Pharmaceuticals announced a collaboration to develop and commercialize several biosimilar medicines worldwide.


 * Add:
 * 2012. Amgen acquired Micromet, a company focused on BiTE technology, in March. In May, Kevin Sharer retired, and Robert Bradway, formerly Amgen's president and chief operating officer, became CEO. In June, Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding Amgen's presence in Turkey and nearby areas. In July, Amgen acquired KAI Pharmaceuticals, developer of Parsabiv (etelcalcetide). Amgen acquired Iceland-based deCODE Genetics in December. Amgen also opened an affiliate in China.
 * 2013. In October, Amgen acquired Onyx Pharmaceuticals, developer of Kyprolis (carfilzomib).


 * Add:
 * 2014. In November, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore. Blincyto (blinatumomab) was approved by the FDA in December.


 * Add to beginning of "2015" bullet:
 * Repatha (evolocumab) was approved by the FDA in August.


 * Add to end of "2015" bullet:
 * In October, the FDA approved Imlygic.


 * Add to end of "2016" bullet:
 * Also in September, the FDA approved Amjevita (adalimumab-atto).


 * Add to end of "2017" bullet:
 * The FDA approved Parsabiv in February and Mvasi (bevacizumab-awwb) in September. In October, the Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons.


 * Add to end of "2018" bullet:
 * In May, Aimovig (erenumab-aooe) was approved by the FDA. Amgen began constructing a next-generation biomanufacturing plant at its West Greenwich, Rhode Island, campus in July.


 * Add to beginning of "2019" bullet:
 * In January, Evenity (romosozumab) received approval in Japan, followed by FDA approval in April. In June, Kanjinti (trastuzumab-anns) was approved by the FDA.


 * Add to end of "2019" bullet:
 * In December, the FDA approved Avsola (infliximab-axxq).


 * Add:
 * 2020. In January, the Amgen Foundation and Harvard University debuted LabXchange, a free online science education platform. Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March. In April, Amgen established Amgen K.K. as the company’s wholly-owned affiliate in Japan.  Amgen announced in July that the United States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the United States District Court for the District of New Jersey and rejected Sandoz's attempt to invalidate the patents on Enbrel. Also in July, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.  Amgen joined the Dow Jones Industrial Average on August 24, 2020. In September, Amgen and Eli Lilly and Company announced a global manufacturing collaboration for COVID-19 antibody therapies. On December 10, Amgen announced that it joined OneTen, a coalition of large employers that aims to hire and advance one million black Americans over the next ten years. Later that month, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.


 * Add to "2021" bullet, before "In July,":
 * The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer. In June, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for atopic dermatitis.


 * Add to end of "2021" bullet:
 * In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases. Amgen began construction on a new biomanufacturing plant in New Albany, Ohio, in November. In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severe asthma. The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level.


 * Add to beginning of "2022" bullet:
 * In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion. The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics.  The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.  Also in February, Amgen issued its first green bond to fund various environmentally friendly initiatives across the company.  The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March.

Thank you for your time and assistance.

JZindler (talk) 20:19, 26 June 2023 (UTC)
 * Done Cherrell410 (talk) 18:30, 27 June 2023 (UTC)
 * Thank you so much! Appreciate your time and your help. JZindler (talk) 18:57, 27 June 2023 (UTC)

NEW COI Edit Request June 2023
Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.

Acquisition history
Add:
 * Otezla (apremilast) (Acq 2019)
 * Rodeo Therapeutics Corporation (Acq 2021)
 * Five Prime Therapeutics (Acq 2021)
 * ChemoCentryx (Acq 2021)

Products

 * Add where alphabetically appropriate (using existing ref names     ):
 * Amjevita (adalimumab)
 * Kanjinti (trastuzumab-anns)
 * Lumakras (sotorasib)
 * Mvasi (bevacizumab-awwb)
 * Otezla (apremilast)
 * Riabni (rituximab-arrx)
 * Tezspire (tezepelumab-ekko)


 * Lastly, add the following line after the last sentence in the lead to give a fuller picture of the company's breadth (these products are substantiated in the article body):
 * Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).

Pipeline and clinical trials

 * Update
 * In December 2013, Amgen had 11 drugs in Phase III clinical trials.
 * to
 * As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I.


 * I think it makes sense to move all the info from November 2014 and March 2015 to the Timeline section, since those candidates are no longer in the pipeline. Since Aimovig's approval is mentioned earlier in the article, it might make sense to just delete it from here as well.


 * After "In 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.", add:
 * In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.


 * In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy). Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.


 * In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19. Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.


 * In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.

Thank you for your time and assistance!!

JZindler (talk) 19:14, 27 June 2023 (UTC)
 * Pictogram voting keep.svg Go ahead: I have reviewed these proposed changes and suggest that you go ahead and make the proposed changes to the page. Mattdaviesfsic (talk) 19:42, 28 June 2023 (UTC)